Ratings of the last 12 months
This list shows every rating MEQIRI has published for a stock, an ETF or a coin, and every change between Strong, Neutral and Weak. For stocks it also shows every valuation signal and its changes.
Counted from the public launch on 7 Nov 2026.
- Price target: none, MEQIRI does not give price targets.
- Fair value: for the valuation signal, that day's fair value, converted like the price. An estimate from the disclosed model, not a price target.
- Validity: until the rating or the valuation signal changes, time horizon about 12 months, recalculated every night.
- Price: last close before publication, converted into dollars at that day's ECB rate; ETFs in euros.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
4 entries
- Gilead Sciences, Inc.13 Nov 2026Valuation signal Undervalued (Before Fairly valued), Fair value $220.46, $167.95
- Gilead Sciences, Inc.11 Nov 2026Valuation signal Fairly valued (Before Undervalued), Fair value $220.46, $170.87
- Gilead Sciences, Inc.7 Nov 2026Neutral (first rating), Score 58, $166.89
- Gilead Sciences, Inc.7 Nov 2026Valuation signal Undervalued (first signal), Fair value $220.46, $166.89
| Date | Security | Rating | Before | Score | Fair value | Price |
|---|---|---|---|---|---|---|
| 13 Nov 2026 | Gilead Sciences, Inc. GILD | Valuation signalUndervalued | Fairly valued | $220.46 | $167.95 | |
| 11 Nov 2026 | Gilead Sciences, Inc. GILD | Valuation signalFairly valued | Undervalued | $220.46 | $170.87 | |
| 7 Nov 2026 | Gilead Sciences, Inc. GILD | Neutral | first rating | 58 | $166.89 | |
| 7 Nov 2026 | Gilead Sciences, Inc. GILD | Valuation signalUndervalued | first signal | $220.46 | $166.89 |
Legal basis: Article 4(1)(i) of Delegated Regulation (EU) 2016/958.
To the disclosures